Tenderwize
Retour à la recherche

Medicinal products with the active substance Erythropoietin (ATC: B03XA01 - in strength up to 10,000 IU per dose unit)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Aug 30, 2026 · 2 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Erythropoietin (ATC: B03XA01 - in der Wirkstärke bis 10.000 IE je Dosiereinheit)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

Buyer may terminate contracts early if exclusive contracts are awarded later; no compensation mentioned.

No estimated value; revenue potential is uncertain.

Submission deadline in 2 days

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for erythropoietin medications (ATC B03XA01, strength up to 10,000 IU per dose unit)
  • Open-house model with continuous application possibility
Afficher le résumé complet

This is an open-house model for non-exclusive discount agreements under German social law (§130a SGB V) for erythropoietin medications (ATC B03XA01, strength up to 10,000 IU per dose unit). The buyer is AOK Sachsen-Anhalt. There is no competitive award; any eligible pharmaceutical company can join. The contract duration is up to 24 months (01.11.2024 to 31.10.2026). No estimated value is provided. The notice is published for transparency only and explicitly states it is not a public procurement.

Risques

Buyer may terminate contracts early if exclusive contracts are awarded later; no compensation mentioned.

No estimated value; revenue potential is uncertain.

Submission deadline in 2 days

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies
  • Must comply with standard contract conditions

Administrative

  • Must request and submit participation documents completely and signed

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Open-house: no competitive award; all eligible companies are accepted.

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Medicinal products with the active substance Erythropoietin (ATC: B03XA01 - in strength up to 10,000 IU per dose unit)

Non-exclusive discount agreements for erythropoietin medications under an open-house model. Any eligible pharmaceutical company can conclude a contract at any time. Contract duration up to 24 months, ending 31.10.2026 regardless of start date.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Critères d'attribution

Open-house: no competitive award; all eligible companies are accepted.

Date limite

Deadline Aug 31, 2026

Détails de la procédure

Date de publication
19 Sep 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
566953-2024

Documents (1)

Appels d'offres similaires